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Abstract 
Purpose: Lactate is an established prognosticator in critical care. However, there still is insufficient evidence about its 
role in predicting outcome in COVID-19. This is of particular concern in older patients who have been mostly affected 
during the initial surge in 2020.
Methods: This prospective international observation study (The COVIP study) recruited patients aged 70 years or 
older (ClinicalTrials.gov ID: NCT04321265) admitted to an intensive care unit (ICU) with COVID-19 disease from March 
2020 to February 2021. In addition to serial lactate values (arterial blood gas analysis), we recorded several param-
eters, including SOFA score, ICU procedures, limitation of care, ICU- and 3-month mortality. A lactate concentration 
≥ 2.0 mmol/L on the day of ICU admission (baseline) was defined as abnormal. The primary outcome was ICU-mortal-
ity. The secondary outcomes 30-day and 3-month mortality.
Results: In total, data from 2860 patients were analyzed. In most patients (68%), serum lactate was lower than 
2 mmol/L. Elevated baseline serum lactate was associated with significantly higher ICU- and 3-month mortality (53% 
vs. 43%, and 71% vs. 57%, respectively, p < 0.001). In the multivariable analysis, the maximum lactate concentration on 
day 1 was independently associated with ICU mortality (aOR 1.06 95% CI 1.02–1.11; p = 0.007), 30-day mortality (aOR 
1.07 95% CI 1.02–1.13; p = 0.005) and 3-month mortality (aOR 1.15 95% CI 1.08–1.24; p < 0.001) after adjustment for 
age, gender, SOFA score, and frailty. In 826 patients with baseline lactate ≥ 2 mmol/L sufficient data to calculate the 
difference between maximal levels on days 1 and 2 (∆ serum lactate) were available. A decreasing lactate concentra-
tion over time was inversely associated with ICU mortality after multivariate adjustment for SOFA score, age, Clinical 
Frailty Scale, and gender (aOR 0.60 95% CI 0.42–0.85; p = 0.004).
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Introduction
The disease caused by Sars-CoV-2, COVID-19, has domi-
nated daily life in numerous intensive care units (ICU) 
worldwide, since the beginning of 2020. Respiratory fail-
ure with or without shock led to high mortality. In ICU 
admitted patients, up to 30–50% of the patients did not 
survive the first month [1–3]. Thus, early and reliable 
identification of complex disease courses is of pivotal 
importance in COVID-19 (Additional file 1).
In emergency and critical care medicine, serum lac-
tate and its kinetics are useful parameters for critically ill 
patients as a marker of severity of illness [4–6]. A signifi-
cant advantage is that the determination of serum lactate 
is widely and rapidly available as a point-of-care measure-
ment [7]. Hyperlactatemia is an indicator of physiological 
stress, and anaerobic metabolism, and a “powerful pre-
dictor of mortality” [6]. Basically, lactate can be used for 
two purposes. It can be used both for risk stratification 
and to monitor the response to therapy. Elevated lactate 
is a diagnostic criterion for septic shock following the 
sepsis-3 consensus. Lactate “clearance” is a target param-
eter for volume substitution in the absence of major liver 
dysfunction [8]. Although serum lactate and its kinetics 
have been applied as an essential diagnostic and target 
parameter in septic patients for more than 20 years, the 
evidence remains scarce for patients suffering from pneu-
monia and ARDS.
Despite this lack of evidence, current guidelines recom-
mend the use of lactate and lactate kinetics in COVID-19 
[9]. Until now, the value of serum lactate and its kinet-
ics in predicting a severe course in COVID-19 is unclear. 
This lack of evidence is especially true in the particularly 
vulnerable population of very old intensive care unit 
patients. Yet, this subgroup has been disproportionally 
affected by the need for ICU admissions and a high mor-
tality [3, 10, 11].
This multicenter study addresses this lack of evidence 
and investigates the value of serum lactate at admission 
and its kinetics for outcome prediction in a large pro-
spectively enrolled population of older ICU patients.
Methods
Design and settings
This multicenter study is part of the Very old Intensive 
care Patients (VIP) project and has been endorsed by the 
European Society of Intensive Care Medicine (ESICM) 
(https:// www. vipst udy. org). The study was registered at 
ClinicalTrials.gov (ID: NCT04321265) and adhered to 
the European Union General Data Privacy Regulation 
(GDPR) directive. This investigation aimed to under-
stand which factors can predict mortality in elderly 
COVID-19 patients to help detect these patients early 
(the COVIP study, COVID-19 in very old intensive care 
patients). As in the previous VIP studies [3, 12, 13], 
national coordinators recruited the intensive care units 
(ICUs), coordinated national and local ethical permis-
sions, and supervised patient recruitment at the national 
level. Ethical approval was mandatory for study participa-
tion. In most countries informed consent was obligatory 
for inclusion. This study extracted patient data from 151 
ICUs from 26 independent countries, including Euro-
pean ICUs, and the Asian, African, and Americas.
Study population
The COVIP study recruited consecutieve patients with 
proven COVID-19 aged 70  years or older who were 
admitted to an ICU. The data set was extracted from the 
COVIP study database on 4th February and contained 
patients from 19th March 2020 to 4th February 2021. 
Data collection started at ICU admission. Data about 
pre-ICU triage were not available. The admission day was 
defined as day 1, and all consecutive days were numbered 
sequentially from that date.
Data collection
All centers used a uniform online electronic case 
report form (eCRF). Only patients with a documented 
highest serum lactate value on days 1 and 2 were 
included for this subgroup analysis (above 2 mmol/L). 
Reporting was possible both in [mg/dL] or [mmol/L], 
depending on local routine. For ease of comparison, 
all laboratory values were converted to [mmol/] (1 mg/
dL = 0.111 mmol/L). The first arterial blood gas (ABG) 
analysis, including  pO2 [mmHg] and the  FiO2 [%], was 
recorded to calculate the  pO2/FiO2-ratio on admission. 
For the sequential organ failure assessment (SOFA) 
score on admission, each element was entered and 
the eCRF calculated the total score. Furthermore, we 
assessed the need for non-invasive or invasive venti-
lation with its duration, prone positioning, tracheos-
tomy, vasopressor use and renal replacement therapy. 
The eCRF also documented any limitation of life-sus-
taining therapy during the ICU-stay. The frailty level 
prior to the acute illness and hospital admission was 
Conclusion: In critically ill old intensive care patients suffering from COVID-19, lactate and its kinetics are valuable 
tools for outcome prediction.
Trial registration number: NCT04321265.
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assessed using the Clinical Frailty Scale (CFS) [3, 12, 
13]. In addition, the eCRF recorded information about 
gender, age, length of ICU stay symptom onset, and 
duration of symptoms before ICU-and hospital admis-
sion. Furthermore, the eCRF asked about the presence 
of preexisting comorbidities.
Lactate and ∆ Lactate
Patients were clustered according to their lac-
tate concentration on ICU admission. The arbi-
trary cutoff value was an initial lactate concentration 
≥ 2.0  mmol/L. A lactate value below 2  mmol/L was 
defined as within the normal range. ∆ Lactate in the 
first 24  h was defined as maximum serum lactate at 
admission minus maximum serum lactate on day 2, 
divided by lactate at admission multiplied by 100 [4]. 
A positive value indicates a fall in serum lactate and a 
negative value signifies rising serum lactate. This has 
been confirmed in larger cohorts as a valuable and 
simple tool for outcome prediction [4].
Data storage
The eCRF and database were hosted on a secure server 
in Aarhus University, Denmark.
Lactate = 100×
















The primary outcome was ICU mortality, secondary out-
comes were 30-day and 3-month mortality. Continuous 
data points were expressed as median and interquartile 
range. Differences between independent groups were cal-
culated using the MannWhitney U test. Categorical data 
are expressed as numbers (percentage). The Chi-square 
test was applied to calculate differences between groups. 
Univariate und multivariable logistic regression analy-
ses were performed to assess associations with baseline 
serum lactate and mortality. We chose the co-variables 
for the multivariable model (age, SOFA score, CFS and 
gender) based on clinical experience and previous lit-
erature [4, 5]. Marginal predictive means with respective 
95% confidence intervals (CI) were calculated. All tests 
were two-sided, and a p value of < 0.05 was considered 
statistically significant. Stata 16 was used for all statistical 
analyses (StataCorp LLC, 4905 Lakeway Drive, College 
Station, Brownsville, Texas, USA).
Fig. 1 CONSORT diagram
Results
Study population
In total, 2860 patients with an available baseline serum 
lactate value were included (Fig.  1). Overall, 68% (1940 
Page 4 of 9Bruno et al. Ann. Intensive Care          (2021) 11:128 
patients) patients had no abnormal elevation of serum 
lactate on the day of admission to the ICU, while 32% 
(920 patients) evidenced an elevated serum lactate 
(Fig. 2) (Table 1).  
Baseline serum lactate
Patients with a lactate greater than/equal to 2  mmol/L 
were older [76 (72–79) vs. 75 (72–78) years, p = 0.007], 
but not more frail [CFS 3 (2–4) vs. 3 (2–4), p = 0.47]. 
Patients with elevated serum lactate had a higher SOFA 
score on admission (Table 1). There were no differences 
in symptom duration or time in the hospital before ICU 
admission [Symptoms prior to hospitalization 2  days 
(1–5) vs. 2  days (1–5), p = 0.96; symptoms prior to 
ICU-admission 6 days (3–9) vs. 7 days (3–10), p = 0.38]. 
Both groups evidenced similar incidences of pre-exist-
ing comorbidities (diabetes, coronary vascular disease, 
chronic renal failure, arterial hypertension, pulmonary 
disease) with the exception for heart failure, which was 
significantly more often in patients with an elevated base-
line serum lactate (18% vs. 14%, p = 0.004).
On day 2, the maximum serum lactate was lower in 
the group of patients with initially elevated serum lactate 
than on the day of admission, but still significantly higher 
than in the group of patients with non-elevated lac-
tate on admission [2.2 mmol/L (1.7–3.0) vs. 1.4 mmol/L 
(1.1–1.8), p < 0.001]. Patients with an elevated baseline 
serum lactate had significantly higher ∆ lactate in 24  h 
than patients with a normal baseline lactate [25% (0–45) 
vs. − 7% (− 33–12), p < 0.001] (Table 1). The two groups 
demonstrated differences in intensive care therapy. 
Patients with an elevated baseline lactate were signifi-
cantly more likely to receive mechanical ventilation [74% 
(677) vs. 70% (1359), p = 0.042], renal replacement ther-
apy [19% (171) vs. 15% (288), p = 0.013], and vasoactive 
drugs [72% (654) vs. 68% (1311), p = 0.038], but prone 
positioning occurred significantly less often in patients 
with an elevated serum lactate [49% (329) vs. 57% (764), 
p < 0.001]. There was no difference regarding non-inva-
sive ventilation [25% (230) vs. 26% (501), p = 0.61] or tra-
cheostomy [19% (173) vs. 19% (364), p = 0.95]. Patients 
with elevated baseline lactate had a significantly higher 
Fig. 2 Distribution of maximum serum lactate values on day 1 (= day 
of ICU-admission), [mmol/L]
Table 1 Baseline characteristics
CFS clinical frailty scale, SOFA score sequential organ failure Assessment for the first 24 h, IQR interquartile range
Variables Baseline lactate ≥ 2 mmol/L Baseline lactate < 2 mmol/L p value
n = 920 (32%) n = 1940 (68%)
Male gender [n] (%) 678 (74%) 1356 (70%) 0.033
Age [years] (IQR) 72–79 (76) 72–78 (75) 0.007
Age 70–79 [n] (%) 715 (78%) 1554 (80%) 0.15
Age 80–89 [n] (%) 194 (21%) 373 (19%) 0.24
Age > 90 [n] (%) 10 (1%) 12 (1%) 0.18
CFS (IQR) 2–4 (3) 2–4 (3) 0.47
Diabetes [n] (%) 334 (37%) 690 (36%) 0.68
Coronary vascular disease [n] (%) 226 (25%) 441 (23%) 0.26
Chronic renal failure [n] (%) 163 (18%) 331 (17%) 0.65
Arterial hypertension [n] (%) 599 (65%) 1325 (69%) 0.086
Pulmonary disease [n] (%) 200 (22%) 456 (24%) 0.30
Heart failure [n] (%) 164 (18%) 264 (14%) 0.004
Lactate on day 1 [mmol/L] (IQR) 2.3–3.8 (2.8) 1.1–1.7 (1.4) < 0.001
SOFA score (IQR) 4–8 (6) 3–8 (5) < 0.001
Symptoms prior to hospitalization (days) 2 (1–5) 2 (1–5) 0.96
Symptoms prior to ICU-admission (days) 6 (3–9) 7 (3–10) 0.38
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ICU-, 30-day and 3-month mortality (Table  2). Length 
of ICU was lower in patients with an elevated base-
line serum lactate [336 h (408) vs. 377 (433), p = 0.037]. 
After exclusion of non-survivors, there was no differ-
ence between both groups [475  h (526) vs. 570  h (552), 
p = 0.48]. Accordingly, the duration of mechanical ven-
tilation was significantly longer in patients with normal 
baseline [343  h (360) vs. 367  h (360), p = 0.026]. Again, 
after exclusion of non-survivors and patients without 
mechanical ventilation, there remained no significant dif-
ference between both groups [323  h (414) vs. 311 (445) 
h, p = 0.41]. Treatment was withheld in 30% (271) of the 
patients with an elevated and in 30% (565) of the patients 
with a normal baseline lactate (p = 0.85). Treatment was 
withdrawn in 21% (188) and 18% (348), respectively 
(p = 0.12).
In a univariate regression analysis, the baseline lactate 
was significantly associated with ICU mortality (OR 1.12 
95% CI 1.07–1.17; p < 0.001), 30-day mortality (OR 1.11 
95% CI 1.06–1.16; p < 0.001) and 3-month mortality (OR 
1.16 95% CI 1.09–1.23; p < 0.001).
In the multivariable analysis, the maximum lactate con-
centration on day 1 was independently associated with 
ICU mortality (aOR 1.06 95% CI 1.02–1.11; p = 0.007), 
30-day mortality (aOR 1.07 95% CI 1.02–1.13; p = 0.005) 
and 3-month mortality (aOR 1.15 95% CI 1.08–1.24; 
p < 0.001) after adjustment for age, SOFA, CFS and sex 
(Fig. 3).
∆ Serum lactate in 24 h
In 826 patients (29%), there was a baseline lactate 
≥ 2 mmol/L and sufficient data to calculate the ∆ serum 
lactate over 24 h. In both sub-groups, patients were pre-
dominantly male (p = 0.37, Table  3). There were no dif-
ferences regarding age, SOFA score on admission, prior 
hospitalizations, or the duration of symptoms before 
ICU admission. The median CFS did not differ (Table 3). 
For pre-existing comorbidities, there was no difference 
between groups except for pulmonary diseases, which 
were significantly more common in those patients with 
rising lactate [27% (n = 58) vs. 19% (n = 117), p = 0.017]. 
Intensive care treatment, especially regarding non-
invasive ventilation [27% (57) vs. 24% (146), p = 0.45], 
vasoactive drugs [70% (151) vs. 74% (444), p = 0.34], 
and renal replacement therapy [21% (45) vs. 18% (112), 
p = 0.42] did not differ between both groups. In patients 
with ∆ serum lactate over 24  h less than 0, intubation 
occurred in 71% (152) compared to 76% (464) (p = 0.12), 
prone positioning was used in 48% (72) compared to 
49% (226) (p = 0.76). During the ICU stay, 40 patients 
with a ∆ serum lactate over 24  h less than 0 received a 
tracheostomy (19%), while this was true for 109 patients 
from the group of patients with a ∆ serum lactate ≥ 0% 
(18%, p = 0.79). Therapy limitations or de-escalations did 
also not differ between groups. Therapy was withheld 
in 29% (62) of the patients with a negative ∆ serum lac-
tate, and in 30% (185) of the other group (p = 0.68), while 
treatment was withdrawn in 19% (40) and 22% (134) of 
the patients, respectively (p = 0.32). Length of stay was 
longer in patients with a ∆ Lactate 24 h > 0% [285 (439) 
h vs. 348 h (400), p = 0.029]. After exclusion of non-sur-
vivors, there was no significant difference between both 
groups [475 (526) h vs. 456 h (552), p = 4.77]. The dura-
tion of mechanical ventilation was significantly longer in 
Table 2 Primary and secondary outcomes
ICU intensive care unit
Variables Baseline Lactate ≥ 2 mmol/L Baseline Lactate < 2 mmol/L p value
n = 920 (32%) n = 1940 (68%)
ICU mortality 465 (53%) 817 (43%) < 0.001
30-day mortality 496 (56%) 854 (46%) < 0.001
3-month mortality 533 (71%) 924 (57%) < 0.001
ICU length of stay (hours, IQR) 336 (408) 377 (433) 0.037
Duration of mechanical ventilation (hours, IQR) 343 (360) 367 (360) 0.026
Fig. 3 Kaplan–Meier for patients with a baseline lactate ≥ 2 mmol/L 
(red line) compared to patients with a baseline lactate < 2 mmol/L 
(blue line) (3-month mortality, ± standard deviation)
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patients with a positive ∆ Lactate 24  h [210  h (390) vs. 
277 (340), p = 0.106]. However, after exclusion of non-
survivors, the duration of mechanical ventilation was 
comparable [323 h (414) vs. 307 h (436) p = 0.364]. ICU 
mortality was significantly higher for patients with ris-
ing lactate [61% (n = 131) vs. 50% (n = 303), p = 0.004, 
Table 4, Fig. 4].
Although not statistically significant, ∆ lactate was 
associated with ICU mortality after multivariable adjust-
ment for age, SOFA score, and gender (aOR 0.997 95% 
CI 0.993–1.000; p = 0.05). A decreasing lactate (∆ lactate 
> 0%) was inversely associated with ICU mortality (OR 
0.63 95% CI 0.46–0.87; p = 0.004) and remained so after 
multivariable adjustment for SOFA score, age, CFS and 
gender (aOR 0.60 95% CI 0.42–0.85; p = 0.004).
Discussion
This sub-group analysis in very old ICU patients with 
COVID-19 examined the value of baseline lactate and 
lactate kinetics as predictors of outcome. Both patients 
with elevated baseline lactate and patients with rising 
lactate suffered from significantly higher ICU-mortality. 
These parameters were independently associated with 
ICU-mortality. To our knowledge, this study represents 
the first prospective observational study in critically ill 
Table 3 Baseline characteristics of the subgroup analysis according to the Δ Lactate 24 h [%]
CFS clinical frailty scale, SOFA score sequential organ failure assessment for the first 24 h, IQR interquartile range
Variables ∆ Lactate 24 h ≤ 0% ∆ Lactate 24 h > 0% p value
n = 215 (26%) n = 611 (74%)
Male gender [n] (%) 152 (71%) 447 (73%) 0.37
Age [years] (IQR) 73–79 (75) 72–79 (76) 0.60
Age 70–79 [n] (%) 180 (80%) 484 (76%) 0.28
Age 80–89 [n] (%) 42 (19%) 143 (23%) 0.22
Age > 90 [n] (%) 3 (1%) 6 (1%) 0.63
CFS (IQR) 2–4 (3) 2–4 (3) 0.13
Diabetes [n] (%) 75 (35%) 231 (38%) 0.43
Coronary vascular disease [n] (%) 46 (22%) 154 (26%) 0.23
Chronic renal failure [n] (%) 43 (20%) 102 (17%) 0.27
Arterial hypertension [n] (%) 140 (65%) 403 (66%) 0.84
Pulmonary disease [n] (%) 58 (27%) 117 (19%) 0.017
Heart failure [n] (%) 42 (20%) 108 (18%) 0.85
SOFA score (IQR) 4–9 (6) 4–8 (6) 0.63
Table 4 Primary and secondary outcomes of the subgroup analysis according to the Δ Lactate 24 h [%]
ICU intensive care unit
Variables ∆ Lactate 24 h ≤ 0% ∆ Lactate 24 h > 0% p value
n = 225 (26%) n = 634 (74%)
ICU mortality 131 (61%) 303 (50%) 0.004
30-day mortality 128 (62%) 331 (55%) 0.077
3-month mortality 139 (79%) 353 (68%) 0.007
ICU length of stay (hours) 285 (439) 348 (400) 0.029
Duration of mechanical ventilation (hours) 210 (390) 277 (340) 0.106
Fig. 4 Kaplan–Meier for patients with a ∆ lactate 24 h > 0% (red line) 
compared to patients with a ∆ lactate 24 h ≤ 0% (blue line) (3-month 
mortality, ± standard deviation)
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old patients with COVID-19 on the value of lactate and 
lactate kinetics for outcome prediction.
These findings are of pivotal importance as lactate and 
its kinetics are already amongst the most important labo-
ratory parameters for diagnosing septic shock and guiding 
treatment. The current sepsis guidelines advocate meas-
urement of lactate at ICU admission and during ICU stay 
as one of the best variables to assess the response to treat-
ment [14]. Indeed, a meta-analysis by Pan et al. included 
seven randomized controlled trials with 1301 patients to 
compare the early lactate clearance-directed therapy to 
central venous oxygen saturation  (ScvO2)-guided ther-
apy as a potentially more effective resuscitation target. 
They concluded that the use of an early lactate clearance-
directed therapy resulted in a decreased in-hospital mor-
tality, shorter ICU stay, shorter mechanical ventilation 
time, and lower APACHE II scores [15].
COVID-19 might be considered as a very unique type 
of sepsis. Thus, the “First Update on the Surviving Sep-
sis Campaign Guidelines on the Management of Adults 
with Coronavirus Disease 2019 (COVID-19) in the 
ICU” were developed [9]. In this statement, the authors 
suggest using dynamic parameters, such as serum lac-
tate measurement, over static parameters to assess fluid 
responsiveness in adults with COVID-19 and shock, 
though with a weak level of evidence [9].
Severe COVID-19 is usually characterized by a fast-
developing pneumonitis and respiratory failure. Currently, 
there are only very limited data about serum lactate values 
in this special type of pneumonitis and in pneumonia in 
general: Gwak et  al. collected consecutive data from 397 
patients who were hospitalized with community acquired 
pneumonia (CAP); 18% of these patients were admitted to 
the ICU. They found an independent association between 
the initial serum lactate concentration and in-hospital 
mortality (aOR1.24; 95% CI 1.01–1.53) [16]. A subgroup 
analysis of the INFAUCI-Study by Pereira et  al. investi-
gated prognostic markers in patients suffering from severe 
community (in most cases bacterial) acquired pneumonia. 
In their analysis, the mean serum lactate on admission was 
higher than in our study (3.0 ± 3.1 mmol/L) and indepen-
dently associated with intra-hospital mortality (OR 1.13; 
95% CI 1.00–1.32, in a sub-group analysis of patients with 
septic shock: OR 1.11; 95% CI 1.00–1.37, respectively). 
Interestingly, they found no association with mortality at 
6 months [17]. In another retrospective analysis involving 
553 patients, Jo et al. showed the non-inferiority of a base-
line serum lactate combined with an early warning score 
compared to established pneumonia scores such as CURB-
65 in predicting outcomes of patients with CAP [18].
Regarding serum lactate levels in COVID-19, the pre-
sent study is in line with Goodall et  al., who found a 
relationship between higher lactate levels (aHR 2.67) 
and an increased mortality in 981 patients [19]. Kayina 
et al. examined 235 patients and demonstrated that non-
survivors had a higher baseline serum lactate (p < 0.01, 
n = 122) [20]. In a very small cohort of 45 ICU-patients 
suffering from COVID-19, Vassiliou et  al. found that 
maximum lactate on admission was independently 
related to 28-day ICU-mortality. Lactate’s area under 
the curve for detecting 28-day ICU mortality was 0.77 
(p = 0.008). Mixed model analysis showed that mean daily 
lactate levels were higher in non-survivors (p < 0.0001). 
Interestingly, when lactate levels were compared to the 
SOFA scores they showed a similar time pattern [21]. A 
retrospective cohort study by Gregoriano et al. included 
99 patients with severe COVID-19. In this cohort, lactate 
on admission was amongst the highest prognostic factors 
for severe COVID-19 progression (lactate on ambient air 
AUC 0.67; lactate with O2 supply AUC 0.70) [22].
However, the present study also reveals another very 
relevant insight into old ICU patients with COVID-
19: almost 70% of patients had no elevated lactate at all 
on admission. This contradicts previous studies, such 
as by Li et  al. [23]. These found, in 204 older patients 
(≥ 60 years) diagnosed with COVID-19, an elevated lac-
tate (median 2.3 mmol/L) in 84% of the patients [23].
Limitations
Our study has some methodological limitations. We lack a 
control group of younger COVID-19 patients for compari-
son or a comparable age cohort of patients who were not or 
could not be admitted to the ICU. In addition, the COVIP 
database does not capture information on time from symp-
toms onset to ICU admission, from pre-ICU care and triage 
or from and level of care, while in the ICU (e.g., nurse-to-
patient ratio). These treatment limitations may affect the 
care of older ICU patients [24]. Participating countries 
varied widely in their care structure. This results in a large 
heterogeneity of treatments. The study also cannot answer 
whether lactate kinetics-guided therapy prospectively 
gives a mortality benefit in critically ill septic patients with 
COVID-19. When lactate values were documented, only 
the first 48 h were recorded, with the highest value per 24 h 
in each case. However, these parameters have been used as 
a benchmark in most studies to date, so the determination 
seems more than adequate to answer the hypothesis. The 
∆ Lactate subgroup analysis lacks patients who died in the 
first 24 h. However, this accounted only for 32 patients of 
the study cohort. Pre-existing liver disease might influence 
lactate and its kinetics. Nevertheless, in the multivariate 
analysis, results have been adjusted to SOFA score which 
includes liver function. Possibly, patients with pulmonary 
artery embolism are more frequently in shock leading to 
elevated lactate. Though, this association is speculative as 
the study did not investigate the occurrence of pulmonary 
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artery embolism as there were no reports of clustered pul-
monary artery emboli when establishing the COVIP study 
design in February 2020.
Conclusion
In critically ill old intensive care patients suffering from 
COVID-19, most critically ill old COVID-19 patients had 
normal serum lactate on admission. However, in those 
who had an elevated lactate, lactate and lactate kinetics 
are valuable tools for outcome prediction.
Supplementary Information
The online version contains supplementary material available at https:// doi. 
org/ 10. 1186/ s13613- 021- 00911-8.
Additional file 1. List of Collaborators: COVIP-Study.
Acknowledgements
The COVIP study group consists of the authors and the following persons: 
Philipp Eller, Michael Joannidis, Dieter Mesotten, Pascal Reper, Sandra Oeyen, 
Walter Swinnen, Nicolas Serck, Elisabeth Dewaele, Edwin Chapeta, Helene Brix, 
Jens Brushoej, Pritpal Kumar, Helene Korvenius Nedergaard, Tim Koch John-
sen, Camilla Bundesen, Maria Aagaard Hansen, Stine Uhrenholt, Helle Bund-
gaard, Jesper Fjølner, Richard Innes, James Gooch, Lenka Cagova, Elizabeth 
Potter, Michael Reay, Miriam Davey, Mohammed Abdelshafy Abusayed, Sally 
Humphreys, Amy Collins, Avinash Aujayeb, Susannah Leaver, Waqas Khaliq, 
Ayman Abdelmawgoad Habib, Mohammed A Azab, Kyrillos Wassim, Yumna A. 
Elgazzar, Rehab Salah, Hazem Maarouf Abosheaishaa, Aliae AR Mohamed Hus-
sein, Ahmed Y. Azzam, Samar Tharwat, Yasmin Khairy Nasreldin Mohamed Ali, 
Omar Elmandouh, Islam Galal, Ahmed Abu-Elfatth, Karam Motawea, Moham-
mad Elbahnasawy, Mostafa Shehata, Mohamed Elbahnasawy, Mostafa Tayeb, 
Nermin Osman, Wafaa Abdel-Elsalam, Aliae Mohamed Hussein, Amer Aldhalia, 
Arnaud Galbois, Bertrand Guidet, Cyril Charron, Caroline Hauw Berlemont, 
Guillaume Besch, Jean-Philippe Rigaud, Julien Maizel, Michel Djibré, Philippe 
Burtin, Pierre Garcon, Saad Nseir, Xavier Valette, Nica Alexandru, Nathalie Marin, 
Marie Vaissiere, Gaëtan Plantefeve, Hervé Mentec, Thierry Vanderlinden, Igor 
Jurcisin, Buno Megarbane, Benjamin Glenn Chousterman, François Dépret, 
Marc Garnier, Sebastien Besset, Johanna Oziel, Alexis Ferre, Stéphane Dauger, 
Guillaume Dumas, Bruno Goncalves, Lucie Vettoretti, Didier Thevenin, Stefan 
Schaller, Muhammed Kurt, Andreas Faltlhauser, Christian Meyer, Milena 
Milovanovic, Matthias Lutz, Gonxhe Shala, Hendrik Haake, Winfried Randerath, 
Anselm Kunstein, Patrick Meybohm, Stephan Steiner, Eberhard Barth, Tudor 
Poerner, Philipp Simon, Marco Lorenz, Zouhir Dindane, Karl Friedrich Kuhn, 
Martin Welte, Ingo Voigt, Hans-Joachim Kabitz, Jakob Wollborn, Ulrich Goebel, 
Sandra Emily Stoll, Detlef Kindgen-Milles, Simon Dubler, Christian Jung, Kristina 
Fuest, Michael Schuster, Stephan Steiner, Antonios Papadogoulas, Francesk 
Mulita, Nikoletta Rovina, Zoi Aidoni, Evangelia Chrisanthopoulou, Eumorfia 
Kondili, Ioannis Andrianopoulos, Mohan Gurjar, Ata Mahmoodpoor, Rand Hus-
sein, Maytham Aqeel Al-Juaifari, Abdullah Khudhur Ahmed Karantenachy, Sigal 
Sviri, Ahmed Elsaka, Brian Marsh, Vittoria Comellini, Farah Al-Ali, Sari Almani, 
Almu´Atasim Khamees, Khayry Al-Shami, Ibrahim Salah El Din, Taha Abubaker, 
Hazem Ahmed, Ahmed Rabha, Abdulmueti Alhadi, Marwa Emhamed, 
Saedah Abdeewi, Abdurraouf Abusalama, Abdulmueti Alhadi, Mohammed 
Huwaysh, Esraa Abdalqader Alghati, Abdelilah Ghannam, Silvio A Namendys-
Sylva, Martijn Groenendijk, Mirjam Evers, Lenneke Van Lelyveld-Haas, Iwan 
Meynaar, Alexander Daniel Cornet, Marieke Zegers, Willem Dieperink, Dylan 
De Lange, Tom Dormans, Michael Hahn, Britt Sjøbøe, Hans Frank Strietzel, 
Theresa Olasveengen, Luis Romundstad, Finn H. Andersen, John George 
Grace Massoud, Aamir Ghafoor Khan, Shahd Al-Qasrawi, Sarah Amro, Anna 
Kluzik, Paweł Zatorski, Tomasz Drygalski, Wojciech Szczeklik, Jakub Klimkiewicz, 
Joanna Solek-Pastuszka, Dariusz Onichimowski, Miroslaw Czuczwar, Ryszard 
Gawda, Jan Stefaniak, Karina Stefanska-Wronka, Ewa Zabul, Ana Isabel Pinho 
Oliveira, Rui Assis, Maria De Lurdes Campos Santos, Henrique Santos, Filipe 
Sousa Cardoso, André Gordinho, Ioana Marina Grintescu, Dana Tomescu, 
Mohamed Raafat Badawy, M José Arche Banzo, Begoña Zalba-Etayo, Patricia 
Jimeno Cubero, Jesús Priego, Gemma Gomà, Teresa Maria Tomasa-Irriguible, 
Susana Sancho, Aida Fernández Ferreira, Eric Mayor Vázquez, Ángela Prado 
Mira, Mercedes Ibarz, David Iglesias, Susana Arias-Rivera, Fernando Frutos-
Vivar, Sonia Lopez-Cuenca, Cesar Aldecoa, David Perez-Torres, Isabel Canas-
Perez, Luis Tamayo-Lomas, Cristina Diaz-Rodriguez, Pablo Ruiz De Gopegui, 
Mahmoud Saleh, Momin Majed Yousuf Hilles, Enas M. Y Abualqumboz, Nawfel 
Ben-Hamouda, Andrea Roberti, Yvan Fleury, Nour Abidi, Joerg C. Schefold, 
Ivan Chau, Alexander Dullenkopf, Mohammad Karam Chaaban, Mohammed 
Mouaz Shebani, Ahmad Hmaideh, Aymen Shaher, Ayca Sultan Sahin, Kemal 
Tolga Saracoglu, Mohammed Al-Sadawi, Richard Pugh, Sara Smuts and Rafat 
Ameen Mohammed Al-Saban.
Authors’ contributions
BW, RRB and CJ analyzed the data and wrote the first draft of the manuscript. 
HF and BG and DL and IS contributed to statistical analysis and improved the 
paper. SB and PHB and JM and MK and AB and AM and FA and AA and BG and 
MC and SC and LF and JF and ML and BM and RM and SO and CÖ and BBP 
and MAB and WS and AV and CW and TZ and JCS and JW gave guidance and 
improved the paper. All authors read and approved the final manuscript.
Funding
Open Access funding enabled and organized by Projekt DEAL. This study was 
endorsed by the ESICM. Free support for running the electronic database and 
was granted from the dep. of Epidemiology, University of Aarhus, Denmark. 
The support of the study in France by a Grant from Fondation Assistance Pub-
lique-Hôpitaux de Paris pour la recherche is greatly appreciated. In Norway, 
the study was supported by a grant from the Health Region West. In addition, 
the study was supported by a Grant from the European Open Science Cloud 
(EOSC). EOSCsecretariat.eu has received funding from the European Union’s 
Horizon Programme call H2020-INFRAEOSC-05-2018-2019, Grant Agreement 
Number 831644. This work was supported by the Forschungskommission of 
the Medical Faculty of the Heinrich-Heine-University Düsseldorf, and No. 2020-
21 to RRB for a Clinician Scientist Track.
Availability of data and materials
Individual participant data that underlie the results reported in this article are 
available to investigators whose proposed use of the data has been approved 
by the COVIP steering committee. The anonymized data can be requested 
from the authors if required.
Declarations
Ethics approval and consent to participate
The primary competent ethics committee was the Ethics Committee of the 
University of Duesseldorf, Germany. Institutional research ethic board approval 
was obtained from each study site.
Consent for publication
The manuscript does not contain any individual person’s data in any form.
Competing interests
The authors declare that they have no competing interests. JCS reports 
grants (full departmental disclosure) from Orion Pharma, Abbott Nutrition 
International, B. Braun Medical AG, CSEM AG, Edwards Lifesciences Services 
GmbH, Kenta Biotech Ltd, Maquet Critical Care AB, Omnicare Clinical Research 
AG, Nestle, Pierre Fabre Pharma AG, Pfizer, Bard Medica S.A., Abbott AG, 
Anandic Medical Systems, Pan Gas AG Healthcare, Bracco, Hamilton Medical 
AG, Fresenius Kabi, Getinge Group Maquet AG, Dräger AG, Teleflex Medical 
GmbH, Glaxo Smith Kline, Merck Sharp and Dohme AG, Eli Lilly and Company, 
Baxter, Astellas, Astra Zeneca, CSL Behring, Novartis, Covidien, Philips Medical, 
Phagenesis Ltd, Prolong Pharmaceuticals and Nycomed outside the submit-
ted work. The money went into departmental funds. No personal financial 
gain applied.
Author details
1 Department of Cardiology, Pulmonology and Vascular Medicine, Medical 
Faculty, Heinrich-Heine-University Duesseldorf, Moorenstraße 5, 40225 Dues-
seldorf, Germany. 2 Department of Anaesthesiology, Perioperative Medicine 
and Intensive Care Medicine, Paracelsus Medical University, Salzburg, Austria. 
Page 9 of 9Bruno et al. Ann. Intensive Care          (2021) 11:128  
3 Department of Clinical Medicine, University of Bergen, Bergen, Norway. 
4 Department of Anaestesia and Intensive Care, Haukeland University 
Hospital, Bergen, Norway. 5 Department of Intensive Care, Aarhus University 
Hospital, Aarhus, Denmark. 6 Department of Intensive Care Medicine, CIBER 
Enfermedades Respiratorias, Corporacion Sanitaria Universitaria Parc Tauli, 
Autonomous University of Barcelona, Sabadell, Spain. 7 Department of Acute 
Medicine, Geneva University Hospitals, Geneva, Switzerland. 8 Department 
of Intensive Care Medicine, Inselspital, Universitätsspital, University of Bern, 
Bern, Switzerland. 9 Deptartment of Medical Intensive Care, Hadassah Medical 
Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, 
Israel. 10 General Intensive Care Unit, Deptartment of Anesthesiology, Critical 
Care and Pain Medicine, Hadassah Medical Center and Faculty of Medicine, 
Hebrew University of Jerusalem, Jerusalem, Israel. 11 Center for Intensive Care 
and Perioperative Medicine, Jagiellonian University Medical College, Krakow, 
Poland. 12 Faculty of Medicine, University of Tripoli, Tripoli, Libya. 13 Division 
of Intensive Care and Emergency Medicine, Department of Internal Medicine, 
Medical University Innsbruck, Innsbruck, Austria. 14 Department of Intensive 
Care 1K12IC, Ghent University Hospital, Ghent, Belgium. 15 Intensive Care Unit 
General Hospital of Larissa, Larissa, Greece. 16 Department of Anesthesiolgy, 
Perioperative and Pain Medicine, Brigham and Women’s Hospital, Harvard 
Medical School, Boston, USA. 17 Hospital Clínico Universitario Lozano Blesa, 
Zaragoza, Spain. 18 Department of Anesthesiology and Intensive Care, Klinikum 
Rechts Der Isar, Technical University of Munich, Munich, Germany. 19 Mater Mis-
ericordiae University Hospital, Dublin, Ireland. 20 Department of Anaesthesia 
and Intensive Care, Ålesund Hospital, Ålesund, Norway. 21 Department of Cir-
culation and Medical Imaging, Norwegian University of Science and Technol-
ogy, Trondheim, Norway. 22 Unidade de Cuidados Intensivos Neurocríticos 
E Trauma, Hospital de São José, Centro Hospitalar Universitário de Lisboa 
Central, Faculdade de Ciências Médicas de Lisboa, Nova Medical School, 
Lisbon, Portugal. 23 General Intensive Care, St George´S University Hospitals 
NHS Foundation Trust, London, UK. 24 Institut Pierre Louis D’Epidémiologie Et 
de Santé Publique, Equipe: épidémiologie hospitalière qualité et organisa-
tion des soins, Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR_S 
1136, 75012 Paris, France. 25 Assistance Publique–Hôpitaux de Paris, service de 
réanimation médicale, Hôpital Saint-Antoine, 75012 Paris, France. 26 Depart-
ment of Intensive Care Medicine, University Medical Center, University Utrecht, 
Utrecht, The Netherlands. 
Received: 31 May 2021   Accepted: 25 July 2021
References
 1. Armstrong RA, Kane AD, Cook TM. Outcomes from intensive care in 
patients with COVID-19: a systematic review and meta-analysis of obser-
vational studies. Anaesthesia. 2020;75(10):1340–9.
 2. Bellelli G, Rebora P, Valsecchi MG, Bonfanti P, Citerio G, Members C-MT. 
Frailty index predicts poor outcome in COVID-19 patients. Intensive Care 
Med. 2020;46(8):1634–6.
 3. Jung C, Flaatten H, Fjolner J, et al. The impact of frailty on survival in 
elderly intensive care patients with COVID-19: the COVIP study. Crit Care. 
2021;25(1):149.
 4. Masyuk M, Wernly B, Lichtenauer M, et al. Prognostic relevance of 
serum lactate kinetics in critically ill patients. Intensive Care Med. 
2019;45(1):55–61.
 5. Bruno RR, Wernly B, Binneboessel S, et al. Failure of lactate clearance 
predicts the outcome of critically ill septic patients. Diagnostics. 2020. 
https:// doi. org/ 10. 3390/ diagn ostic s1012 1105.
 6. Hernandez G, Bellomo R, Bakker J. The ten pitfalls of lactate clearance in 
sepsis. Intensive Care Med. 2019;45(1):82–5.
 7. Wernly B, Bakker J, Jung C. Venous blood lactate concentrations in 
patients with shock: Interesting but not really helpful. J Crit Care. 
2020;58:125–6.
 8. Singer M, Deutschman CS, Seymour CW, et al. The third international 
consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 
2016;315(8):801–10.
 9. Alhazzani W, Evans L, Alshamsi F, et al. Surviving sepsis campaign 
guidelines on the management of adults with coronavirus disease 2019 
(COVID-19) in the ICU: 55. Crit Care Med. 2021;49(3):e219-34.
 10. Phua J, Weng L, Ling L, et al. Intensive care management of coronavirus 
disease 2019 (COVID-19): challenges and recommendations. Lancet 
Respir Med. 2020;8(5):506–17.
 11. Smorenberg A, Peters EJG, van Daele PLA, Nossent EJ, Muller M. How 
does SARS-CoV-2 targets the elderly patients? A review on potential 
mechanisms increasing disease severity. Eur J Intern Med. 2021;83:1–5.
 12. Flaatten H, De Lange DW, Morandi A, et al. The impact of frailty on ICU 
and 30-day mortality and the level of care in very elderly patients (≥ 80 
years). Intensive Care Med. 2017;43(12):1820–8.
 13. Guidet B, de Lange DW, Boumendil A, et al. The contribution of frailty, 
cognition, activity of daily life and comorbidities on outcome in acutely 
admitted patients over 80 years in European ICUs: the VIP2 study. Inten-
sive Care Med. 2020;46(1):57–69.
 14. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: inter-
national guidelines for management of severe sepsis and septic shock: 
2008. Crit Care Med. 2008;36(1):296–327.
 15. Pan J, Peng M, Liao C, Hu X, Wang A, Li X. Relative efficacy and safety of 
early lactate clearance-guided therapy resuscitation in patients with 
sepsis: a meta-analysis. Medicine. 2019;98(8): e14453.
 16. Gwak MH, Jo S, Jeong T, et al. Initial serum lactate level is associated with 
inpatient mortality in patients with community-acquired pneumonia. Am 
J Emerg Med. 2015;33(5):685–90.
 17. Pereira JM, Goncalves-Pereira J, Ribeiro O, Baptista JP, Froes F, Paiva JA. 
Impact of antibiotic therapy in severe community-acquired pneumonia: 
data from the Infauci study. J Crit Care. 2018;43:183–9.
 18. Jo S, Jeong T, Lee JB, Jin Y, Yoon J, Park B. Validation of modified early 
warning score using serum lactate level in community-acquired pneu-
monia patients. The national early warning score-lactate score. Am J 
Emerg Med. 2016;34(3):536–41.
 19. Goodall JW, Reed TAN, Ardissino M, et al. Risk factors for severe disease 
in patients admitted with COVID-19 to a hospital in London, England: a 
retrospective cohort study. Epidemiol Infect. 2020;148:e251.
 20. Kayina CA, Haritha D, Soni L, et al. Epidemiological & clinical character-
istics & early outcome of COVID-19 patients in a tertiary care teaching 
hospital in India: a preliminary analysis. Indian J Med Res. 2020;152(1 & 
2):100–4.
 21. Vassiliou AG, Jahaj E, Ilias I, et al. Lactate kinetics reflect organ dysfunction 
and are associated with adverse outcomes in intensive care unit patients 
with COVID-19 pneumonia: preliminary results from a GREEK single-cen-
tre study. Metabolites. 2020. https:// doi. org/ 10. 3390/ metab o1010 0386.
 22. Gregoriano C, Koch D, Haubitz S, et al. Characteristics, predictors and 
outcomes among 99 patients hospitalised with COVID-19 in a tertiary 
care centre in Switzerland: an observational analysis. Swiss Med Wkly. 
2020;150: w20316.
 23. Li P, Chen L, Liu Z, et al. Clinical features and short-term outcomes of 
elderly patients with COVID-19. Int J Infect Dis. 2020;97:245–50.
 24. Flaatten H, deLange D, Jung C, Beil M, Guidet B. The impact of end-of-life 
care on ICU outcome. Intensive Care Med. 2021. https:// doi. org/ 10. 1007/ 
s00134- 021- 06365-7.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
